Johnson & Johnson (J&J) has reported more data supporting the efficacy of its intravesical drug release system TAR-200 in ...

Early findings from Johnson & Johnson’s Phase IIb SunRISe-1 trial show the promise of TAR-200 in patients with Bacillus ...

In a study from Dr. Zlotta’s group published in 2025 in the Journal of Urology, 1 they suggest that better tools are needed to minimize interobserver variability in pathological grading. This is ...

The CR rate was consistent across subgroups including men and women, patients with and without papillary disease, and ...

TAR-200 demonstrated a high disease-free survival and bladder preservation rates in BCG-unresponsive, high-risk ...

Among patients with non-muscle-invasive bladder cancer (NMIBC), neoadjuvant treatment with mitomycin C prior to transurethral ...

Chris Cotton is raising money for cancer centers after being told the day after his 50th birthday that what he thought was a ...

Oncologists at AUA 2025 share promising data, including sasanlimab, cretostimogene grenadenorepvec, and TAR-200 in NMIBC.

CG Oncology, Inc. (NASDAQ:CGON) announced on Saturday that cretostimogene grenadenorepvec monotherapy data were presented at ...

With an FDA review underway, Johnson & Johnson is aiming to “fundamentally change” how bladder cancer is treated. | With an ...

Shares of Pfizer Inc (PFE) rose 0.6% in early premarket trading on Monday, tracking a three-week high, after the drugmaker ...

A dad who thought he had a UTI was diagnosed with stage four bladder cancer and given 24 months to live. Dad-of-two Chris ...